JIANGSU EAST-MAB BIOMEDICAL TECHNOLOGY CO LTD

Overview

JIANGSU EAST-MAB BIOMEDICAL TECHNOLOGY CO LTD is an active pharmaceutical ingredient (API) supplier with 23 active FDA Type II Drug Master Files, covering RECOMBINANT ANTI-HUMAN CD16 MAB; RECOMBINANT ANTI-HUMAN CD28 MAB; RECOMBINANT ANTI-HUMAN CD3 MAB; RECOMBINANT HUMAN ACTIVIN A; RECOMBINANT HUMAN BFGF; RECOMBINANT HUMAN BMP 2.

Core services & business areas

Active pharmaceutical ingredients supplied

Substances JIANGSU EAST-MAB BIOMEDICAL TECHNOLOGY CO LTD is evidenced to supply (US FDA Drug Master File or EU CEP). Open any ingredient to see its full supplier landscape, CAS number and patent status.

API / Drug Master Files

JIANGSU EAST-MAB BIOMEDICAL TECHNOLOGY CO LTD holds 23 active (23 total) FDA Type II Drug Master Files — identifying it as an active-substance / API supplier. Type II DMFs are filed with the FDA to support the use of an active pharmaceutical ingredient in drug applications.

• RECOMBINANT HUMAN TRANSFERRINActive2025-08-13
• RECOMBINANT HUMAN M-CSF (E. COLI-EXPRESSED)Active2025-07-17
• RECOMBINANT HUMAN INTERLEUKIN-7Active2025-03-27
• RECOMBINANT HUMAN BMP 2Active2025-03-27
• RECOMBINANT HUMAN IL-18 (E.COLI-EXPRESSED)Active2025-03-27
• RECOMBINANT HUMAN IFNYActive2025-03-05
• RECOMBINANT ANTI-HUMAN CD3 MABActive2025-03-04
• RECOMBINANT HUMAN IL-1A (E.COLI-EXPRESSED)Active2025-02-24
• RECOMBINANT HUMAN G-CSFActive2024-09-24
• RECOMBINANT HUMAN GM-CSFActive2024-09-21
• RECOMBINANT HUMAN INTERLEUKIN-12Active2024-09-20
• RECOMBINANT HUMAN BFGFActive2024-09-11
• RECOMBINANT HUMAN PDGF-BBActive2024-09-08
• RECOMBINANT HUMAN TPOActive2024-09-07
• RECOMBINANT ANTI-HUMAN CD28 MABActive2024-09-04

Showing 15 of 23 Drug Master Files.

FDA compliance signals

No FDA recalls, Warning Letters, or Form 483 observations are linked to JIANGSU EAST-MAB BIOMEDICAL TECHNOLOGY CO LTD in our records. PharmaTek screens the full directory against live FDA enforcement data.